Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2018 (2018), Article ID 5895903, 4 pages
https://doi.org/10.1155/2018/5895903
Case Report

Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease

Department of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China

Correspondence should be addressed to Yun Ling; moc.liamtoh@700624011a

Received 26 August 2017; Accepted 7 December 2017; Published 23 January 2018

Academic Editor: Sergio Storti

Copyright © 2018 Feng Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. C. Fajgenbaum, F. van Rhee, and C. S. Nabel, “HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy,” Blood, vol. 123, no. 19, pp. 2924–2933, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Kawabata, N. Kadowaki, M. Nishikori et al., “Clinical features and treatment of multicentric Castleman’s disease : a retrospective study of 21 Japanese patients at a single institute,” Journal of Clinical and Experimental Hematopathology, vol. 53, no. 1, pp. 69–77, 2013. View at Publisher · View at Google Scholar
  3. F. van Rhee, K. Stone, S. Szmania, B. Barlogie, and Z. Singh, “Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy,” Clinical Advances in Hematology and Oncology, vol. 8, no. 7, pp. 486–498, 2010. View at Google Scholar
  4. D. M. P. Cronin and R. A. Warnke, “Castleman disease: an update on classification and the spectrum of associated lesions,” Advances in Anatomic Pathology, vol. 16, no. 4, pp. 236–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. W. Muskardin, B. A. Peterson, and J. A. Molitor, “Castleman disease and associated autoimmune disease,” Current Opinion in Rheumatology, vol. 24, no. 1, pp. 76–83, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Gonzalez Garcia, M. A. Moreno Cobo, and J. L. Patier de la Pena, “Current diagnosis and treatment of Castleman’s disease,” Revista Clinica Espanola, vol. 216, no. 3, pp. 146–156, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. H. E. El-Osta and R. Kurzrock, “Castleman’s disease: from basic mechanisms to molecular therapeutics,” Oncologist, vol. 16, no. 4, pp. 497–511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Tal, G. Haber, M. J. Cohen et al., “Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant,” International Journal of Hematology, vol. 93, no. 5, pp. 677–680, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Yu, M. Tu, J. Cortes et al., “Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease,” Blood, vol. 129, no. 12, pp. 1658–1668, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Ades, M. A. Sekeres, A. Wolfromm et al., “Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine,” Leukemia Research, vol. 37, no. 6, pp. 609–613, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Alfonso, G. Montalban-Bravo, K. Takahashi et al., “Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents,” American Journal of Hematology, vol. 92, no. 7, pp. 599–606, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Peker, E. Padron, J. M. Bennett et al., “A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution,” Acta Haematologica, vol. 133, no. 2, pp. 249–256, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Grignano, A. Mekinian, T. Braun et al., “Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: a series of 26 cases and literature review,” Leukemia Research, vol. 47, pp. 136–141, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Hadjadj, M. Michel, M. P. Chauveheid et al., “Immune thrombocytopenia in chronic myelomonocytic leukemia,” European Journal of Haematology, vol. 93, no. 6, pp. 521–526, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. V. Elbaek, A. L. Sorensen, and H. C. Hasselbalch, “Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?” Leukemia and Lymphoma, vol. 57, no. 8, pp. 1793–1799, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Haque and R. van Kirk, “Three patients with both Hodgkin’s lymphoma and Castleman’s disease: clinicopathologic correlations and lack of association with HHV-8,” Indian Journal of Medical and Paediatric Oncology: Official Journal of Indian Society of Medical & Paediatric Oncology, vol. 30, no. 2, pp. 76–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. U. Zanetto, F. P. Pagani, and C. Perez, “Interfollicular Hodgkin’s lymphoma and Castleman’s disease,” Histopathology, vol. 48, no. 3, pp. 317–319, 2006. View at Publisher · View at Google Scholar · View at Scopus